Novel potent and balanced dual CDK6/PIM1 inhibitor, showing high kinase selectivity and displaying stronger potency in reducing the burden of AML than palbociclib and SMI-4a in vivo

Novel potent CDK8 inhibitor

Novel potent and selective dual inhibitor of CDK8 and CDK19

Potent dual inhibitor of CDK8/19, suppressing phosphorylated STAT1 in various cancer cells

Novel potent and selective inhibitor of CDK8, also modulating CDK19

Novel inhibitor of CDK8

Novel highly potent, selective, permeable CDK8 inhibitor

Novel potent and highly selective CDK8 inhibitor, with no apparent potential for time-dependent CYP3A4 inhibition

Novel potent CDK8 inhibitor

Novel CDK8 inhibitor

Novel CDK8 inhibitor

Novel CDK8 inhibitor

Novel Potent and Selective CDK9 Degrader for Targeting Transcription Regulation in Triple-Negative Breast Cancer

Novel potent dual inhibitor of CDK9 and BET proteins with balanced activities of BRD4 (IC50 = 12.7 nM) and CDK9 (IC50 = 22.4 nM), as well as good antiproliferative activities on a small cancer cell panel

Highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity

Novel inhibitor of the cyclin-dependent kinase 9 (CDK9)

Potent and selective ATP competitiive inhibitor of cycB-CDK1, cycE-CDK2, and cycD1-CDK4

Novel potent inhibitor of cyclin-dependent kinases (CDKs) 2, 5, and 9, displaying activities across more than 60 cancer cell lines

Novel photoaffinity probe for cyclin-dependent kinase (CDK) family

Novel anti-hepatitis B virus (HBV) agent

Highly permeable non-Pglycoprotein substrate

Potent Antagonist for the Human Thyrotropin Receptor (TSHR)